Literature DB >> 31795658

Mouse methods and models for studies in hearing.

Kevin K Ohlemiller1.   

Abstract

Laboratory mice have become the dominant animal model for hearing research. The mouse cochlea operates according to standard "mammalian" principles, uses the same cochlear cell types, and exhibits the same types of injury as found in other mammals. The typical mouse lifespan is less than 3 years, yet the age-associated pathologies that may be found are quite similar to longer-lived mammals. All Schuknecht's types of presbycusis have been identified in existing mouse lines, some favoring hair cell loss while others favor strial degeneration. Although noise exposure generally affects the mouse cochlea in a manner similar to other mammals, mice appear more prone to permanent alterations to hair cells or the organ of Corti than to hair cell loss. Therapeutic compounds may be applied systemically or locally through the tympanic membrane or onto (or through) the round window membrane. The thinness of the mouse cochlear capsule and annular ligament may promote drug entry from the middle ear, although an extremely active middle ear lining may quickly remove most drugs. Preclinical testing of any therapeutic will always require tests in multiple animal models. Mice constitute one model providing supporting evidence for any therapeutic, while genetically engineered mice can test hypotheses about mechanisms.

Entities:  

Year:  2019        PMID: 31795658     DOI: 10.1121/1.5132550

Source DB:  PubMed          Journal:  J Acoust Soc Am        ISSN: 0001-4966            Impact factor:   1.840


  10 in total

1.  Traumatic-noise-induced hair cell death and hearing loss is mediated by activation of CaMKKβ.

Authors:  Fan Wu; Kayla Hill; Qiaojun Fang; Zuhong He; Hongwei Zheng; Xianren Wang; Hao Xiong; Su-Hua Sha
Journal:  Cell Mol Life Sci       Date:  2022-04-19       Impact factor: 9.261

2.  Trigeminal Contributions to the Dorsal Cochlear Nucleus in Mouse.

Authors:  Timothy S Balmer; Laurence O Trussell
Journal:  Front Neurosci       Date:  2021-07-28       Impact factor: 5.152

Review 3.  Current Advances in Adeno-Associated Virus-Mediated Gene Therapy to Prevent Acquired Hearing Loss.

Authors:  Fan Wu; Kumar Sambamurti; Suhua Sha
Journal:  J Assoc Res Otolaryngol       Date:  2022-08-24

4.  Age-Related Inflammation and Oxidative Stress in the Cochlea Are Exacerbated by Long-Term, Short-Duration Noise Stimulation.

Authors:  Verónica Fuentes-Santamaría; Juan Carlos Alvarado; Susana Mellado; Pedro Melgar-Rojas; María Cruz Gabaldón-Ull; José J Cabanes-Sanchis; José M Juiz
Journal:  Front Aging Neurosci       Date:  2022-04-05       Impact factor: 5.702

Review 5.  Investigational Medicinal Products for the Inner Ear: Review of Clinical Trial Characteristics in ClinicalTrials.gov.

Authors:  Colleen G Le Prell
Journal:  J Am Acad Audiol       Date:  2022-05-24       Impact factor: 1.245

6.  Noise-Induced Hearing Loss and its Prevention: Current Issues in Mammalian Hearing.

Authors:  Colleen G Le Prell; Troy A Hackett; Ramnarayan Ramachandran
Journal:  Curr Opin Physiol       Date:  2020-07-12

7.  Noise-induced hearing loss and its prevention: Integration of data from animal models and human clinical trials.

Authors:  Colleen G Le Prell; Tanisha L Hammill; William J Murphy
Journal:  J Acoust Soc Am       Date:  2019-11       Impact factor: 1.840

8.  Octave band noise exposure: Laboratory models and otoprotection efforts.

Authors:  Sarah N Gittleman; Colleen G Le Prell; Tanisha L Hammill
Journal:  J Acoust Soc Am       Date:  2019-11       Impact factor: 2.482

Review 9.  What's the buzz? The neuroscience and the treatment of tinnitus.

Authors:  A Henton; T Tzounopoulos
Journal:  Physiol Rev       Date:  2021-03-26       Impact factor: 46.500

Review 10.  Use of the guinea pig in studies on the development and prevention of acquired sensorineural hearing loss, with an emphasis on noise.

Authors:  Gaëlle Naert; Marie-Pierre Pasdelou; Colleen G Le Prell
Journal:  J Acoust Soc Am       Date:  2019-11       Impact factor: 2.482

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.